Limitations include the single-center setting, multiple cancer and ICI types, limited sample size that precluded subgroup analyses (such as type of cancer, ICI, or irAE), and the absence of tumor- and patient-related predictive variables such as PD-L1 expression, tumor mutational burden, steroid use, antibiotic exposure, and line of therapy. This evidence concerns the gene CD274 and neoplasm.